"Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study

Andrea Nicolini, Angelo Carpi, Claudio Michelassi, Claudio Spinelli, Massimo Conte, Paolo Miccoli, M. Fini, R. Giardino

Research output: Contribution to journalArticle

Abstract

Objectives. - Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means. We hypothesised that carcinoembryonic antigen (CEA), tissue polipeptyde antigen (TPA), breast cancer associated antigen 115 D8/DF3 (CA15.3) tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients. Methods. - From October 1981 to May 1999, 68 (62%) of 109 patients with distant metastases were recruited. Thirty-six (53%) received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15.3 tumour marker panel and negative instrumental examinations ("tumour marker guided" treatment) and 32 (47%) were treated only after radiological confirmation of metastases (conventional treatment). The prognostic factors of the two groups did not show any statistically significant difference. Results. - The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases (lead time) was significantly prolonged in the 36 patients with "tumour marker guided" treatment (17.3±13.1 vs. 2.9±2.9 months, P

Original languageEnglish
Pages (from-to)452-459
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume57
Issue number10
DOIs
Publication statusPublished - Dec 2003

Keywords

  • Breast cancer
  • Metastasis
  • Treatment
  • Tumour markers

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of '"Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: Final report of a 7-year study'. Together they form a unique fingerprint.

  • Cite this